ACP-204
Asset
Serotonin 5-HT2A receptor inverse agonist / antagonist
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- HTR2A
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Alzheimer's disease psychosis
Phase 2, Recruiting, NCT06159673, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors4
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.